Bayer: buys rest of BlueRock Therapeutics

(CercleFinance.com) - On Thursday Bayer announced the acquisition of all of BlueRock Therapeutics' capital, a US biotech company it helped create in 2016.
 

The German pharmaceutical giant - which already held a 40.8% stake in the cell therapy specialist - will pay some 600 million dollars to buy out the remaining capital, hence valuing BlueRock at around 1 billion dollars.

As the owner of a stem cell-based platform, BlueRock is currently exploring several therapeutic treatment options in the fields of neurology, cardiology and immunology.

The company plans to start an initial clinical trial of a drug against Parkinson's disease by the end of the year.


Copyright (c) 2019 CercleFinance.com. All rights reserved.